Cost-Effectiveness of Boceprevir Co-Administration versus Pegylated Interferon-α2b and Ribavirin Only for Patients with Hepatitis C Genotype 1 in Singapore
Free accessResearch articleFirst published online February, 2015
Cost-Effectiveness of Boceprevir Co-Administration versus Pegylated Interferon-α2b and Ribavirin Only for Patients with Hepatitis C Genotype 1 in Singapore
Patients infected with chronic HCV genotype 1 experience liver complications as the disease progresses. This study aims to project the long-term reduction of liver complications and cost-effectiveness of treatment strategies, including co-administrating boceprevir (BOC) with pegylated interferon-α2b (PEG-IFN) and ribavirin compared with standard of care (SOC) of PEG-IFN and ribavirin only.
Methods
A Markov model was created to estimate the expected costs and quality-adjusted life-years (QALYs) associated with treatment strategies outlined in the BOC package insert in Singapore. Patient characteristics were from pivotal trials, the transition probabilities and QALYs were estimated from publications, and the pharmaceutical and health status costs were obtained from a public hospital in Singapore. The threshold of cost-effectiveness was chosen as 65,000 SGD for this study.
Results
For treatment-naive patients, BOC is highly cost-effective compared with SOC (179 SGD/QALY) and cost-saving for patients who have failed prior treatment, due to higher QALYs from better sustained virological response (SVR) and lower costs from avoidance of complications. Sub-group analyses show that BOC is cost-effective for non-cirrhotic treatment-experienced patients and null responders. It out-performs SOC for treatment-naive non-cirrhotic and cirrhotic patients who have failed prior treatment. Even after adjusting for higher prevalence of favourable IL28B genotype in Asians, BOC is cost-effective compared with SOC. Only untreated cirrhotic patients showed inconclusive cost-effectiveness for BOC.
Conclusions
Compared with SOC, BOC prevents more HCV liver complications from HCV genotype 1, particularly in patients who have failed previous SOC. Improved SVR and shortened duration of treatment result in BOC being potentially cost-saving or cost-effective in an Asian population.
Mohd HanafahK., GroegerJ., FlaxmanA.D., WiersmaS.T.Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to hepatitis C virus seroprevalence.Hepatology2013; 57: 1333–1342.
3.
LiS.C., LimS.G., YeohK.G.A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore.J Clin Gastroenterol2004; 38: S136–S143.
FerranteS.A., ChhatwalJ., BrassC.A.Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.BMC Infect Dis2013; 13: 190.
7.
ElbashaE.H., ChhatwalJ., FerranteS.A., El KhouryA.E., LairesP.A.Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal.Appl Health Econ Health Policy2013; 11: 65–78.
8.
RangnekarA.S., FontanaR.J.Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients.Aliment Pharmacol Ther2012; 36: 104–114.
9.
PoordadF., BronowickJ.P., GordonS.C.Factors that predict response of patients with hepatitis C virus infection to boceprevir.Gastroenterology2012; 143: 608–618.
10.
Jiménez-SousaM.A., Fernández-RodríguezA., Guzmán-FulgencioM., García-ÁlvarezM., ResinoS.Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment related clearance for patients with hepatitis C.BMC Med2013; 11: 6.
2012 Gross domestic product (GDP).Department of Statistics, Singapore. (Updated February 2013. Accessed 25 February 2013.) Available from http://www.singstat.gov.sg/stats/keyind.html.
13.
LiuS., CiprianoL.E., HolodniyM., OwensD.K., Goldhaber-FiebeertJ.D.New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis.Ann Intern Med2012; 156: 279–290.
14.
TheinH.H., YiQ., DoreG.J., KrahnM.D.Estimation of stage specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression.Hepatology2008; 48: 418–431.
15.
FattovichG., GiustinaG., DegosF.Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients.Gastroenterology1997; 112: 463–472.
16.
GentiliniP., LaffiG., La VillaG.Long course and prognostic factors of virus-induced cirrhosis of the liver.Am J Gastroenterol1997; 92: 66–72.
17.
SerfatyL., AumaîtreH., ChazouillèresO.Determinants of outcome of compensated hepatitis C virus-related cirrhosis.Hepatology1998; 27: 1435–1440.
18.
BenvegnùL., NoventaF., BernardinelloE., PontissoP., GattaA., AlbertiA.Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development.Gut2001; 48: 110–115.
19.
SangiovanniA., PratiG.M., FasaniP.The natural history of compensated cirrhosis due to hepatitis C virus: A 17 year cohort study of 214 patients.Hepatology2006; 43: 1303–1310.
20.
TsukumaH., HiyamaT., TanakaS.Risk factors for hepatocellular carcinoma among patients with chronic liver disease.N Engl J Med1993; 328: 1797–1801.
21.
BrunoS., SiliniE., CrosignaniA.Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study.Hepatology1997; 25: 754–758.
22.
YoshidaH., ShiratoriY., MoriyamaM.Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan.Ann Intern Med1999; 131: 174–181.
23.
TateyamaM., YatsuhashiH., TauraN.Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus.J Gastroenterol2011; 46: 92–100.
24.
PlanasR., BallestéB., AlvarezM.A.Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients.J Hepatol2004; 40: 823–830.
25.
DavisG.L., AlterM.J., El-SeragH., PoynardT., JenningsL.W.Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression.Gastroenterology2010; 138: 513–521.
26.
ThuluvathP.J., GuidingerM.K., FungJ.J., JohnsonL.B., RayhillS.C., PelletierS.J.Liver transplantation in the United States, 1999–2008.Am J Transplant2010; 10: 1003–1019.
27.
LangK., DanchenkoN., GondekK., ShahS., ThompsonD.The burden of illness associated with hepatocellular carcinoma in the United States.J Hepatol2009; 50: 89–99.
28.
SaabS., HuntD.R., StoneM.A., McCluneA., TongM.J.Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.Liver Transpl2010; 16: 748–759.
29.
CardosoA.C., MoucariR., Figueiredo-MendesC.Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.J Hepatol2010; 52: 652–657.
WolfeR., RoysE., MerionR.Trends in organ donation and transplantation in the United States, 1999–2008.Am J Transplant2010; 10: 961–972.
32.
SiebertU., SroczynskiG., RossolS.Cost effectiveness of peginterferon-2b plus ribavirin versus interferon-2b plus ribavirin for initial treatment of chronic hepatitis C.Gut2003; 52: 425–432.
33.
WilsonJ., YaoG., RafteryJ.A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment.Health Technol Assess2007; 11: 1–202.
34.
GerkensS., NechelputM., AnnemansL.A health economic model to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C.J Viral Hepat2007; 14: 523–536.
